AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Source: Wikipedia (CC BY-SA)
According to 36Kr, Dizal Medical announced that on July 14, 2026, it signed a licensing agreement with AstraZeneca granting global exclusive rights to develop and commercialize Shuwozhe, with the agreement taking effect on August 31, 2026, and the company receiving a 600 million USD upfront payment.
According to The Guardian Business, AstraZeneca is investing $2 billion in Summit Therapeutics to co-develop and test anti-cancer drugs, with plans to collaborate on a series of studies and to broaden the reach of its ADC portfolio alongside next-generation immunotherapies, including PD-1 targeting bispecifics.
According to The Guardian Business, AstraZeneca is investing $2 billion in Summit Therapeutics to co-develop and test anti-cancer drugs, with plans to collaborate on a series of studies and to broaden the reach of its ADC portfolio alongside next-generation immunotherapies, including PD-1 targeting bispecifics.
